Nonacus

Nonacus is a UK-based leader in precision oncology, transforming how cancer is detected and managed. Headquartered in Birmingham and working with scientists and clinicians worldwide, we are building an end-to-end genetic testing workflow designed to make early cancer detection simpler, faster, and accessible for all.

Our flagship innovation, GALEAS™ Bladder, is a non-invasive genetic urine test that helps assess bladder cancer risk and triage patients presenting with haematuria. By helping clinicians identify patients that require further investigation, GALEAS™ Bladder can reduce unnecessary invasive procedures, optimise clinical resources, and improve patient experience.

Nonacus is actively seeking commercial partners, distributors, and healthcare providers across the Middle East to drive adoption, expand market access, and deliver measurable clinical and economic value through smarter bladder cancer diagnostics.